Evogene (NASDAQ: EVGN) — Company Overview, News & Financial Data
Evogene leverages computational biology to enhance agriculture and health, addressing food security and environmental challenges.
Evogene
Evogene (TASE:EVGN) (NASDAQ:EVGN) is a pioneering firm dedicated to leveraging computational biology to accelerate the development of products in the life sciences field. The company's operations span across multiple sectors, including agriculture, human health, and industrial applications, with projects focused on improving crop yields, developing effective therapeutics, and finding efficient bio-based solutions to conventional chemical processes. With an advanced computational platform, Evogene aims to discover and harness the vast potential of the biological world, addressing some of the most pressing issues faced by humanity, such as food security, disease, and environmental sustainability. Through its diverse and innovative projects, Evogene strives to achieve its objectives of creating sustainable solutions that benefit both the planet and its inhabitants.
Snapshot
Operations
Products and/or services of Evogene
- AgPlenus - develops effective and sustainable agrochemical products for crop protection.
- Lavie Bio - focuses on improving agricultural productivity and sustainability through microbiome-based products.
- Canonic - specializes in the development of medical cannabis products.
- Biomica - engages in the development of therapeutics based on the human microbiome for immune modulation and cancer.
- Ag-Seeds - leverages computational biology to enhance seed traits for improved crop performance.
- Breeding by Design - offers a novel approach to plant breeding, integrating computational biology for enhanced crop traits.
Evogene executive team
- Ofer HavivCEO, President, CFO & Director
- Yoash ZoharChief Executive Officer of Casterra Ag Ltd.
- Dan Jacob GelvanChief Executive Officer of Ag Plenus Ltd.
- Ilia ZhidkovChief Technology Officer
- Liat Foigel WejgmanVice President of Human Resources
- Gabi TarcicChief Development Officer
Latest news about Evogene
Evogene Q2 net loss narrows to $1.8 million
United StatesEvogene cancer combination therapy meets safety goal in early trial
United StatesEvogene revenue contracts to $0.3 million as Q1 net loss widens
United StatesEvogene pivots toward ChemPass AI™ platform as restructuring narrows 2025 loss
United StatesEvogene taps biotech veteran Dr. Olga Nissan to lead AI-driven business growth
United States
Key financials
Reported results for Evogene, in USD.
- Market cap
- 6.5M
- Revenue (TTM)
- 1.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 3.9M | -14M | -8.5M | |
| 5.6M | -18.8M | -16.5M | |
| 3M | -22.2M | -23.9M | |
| 1.7M | -26.9M | -26.6M |